# Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)

> **NCT00813332** · PHASE4 · UNKNOWN · sponsor: **Simcere Pharmaceutical Co., Ltd** · enrollment: 300 (estimated)

## Conditions studied

- Advanced NSCLC
- Recurrent NSCLC

## Interventions

- **DRUG:** Endostar(rh recombinant endostatin) plus Docetaxel
- **DRUG:** Placebo plus Docetaxel

## Key facts

- **NCT ID:** NCT00813332
- **Lead sponsor:** Simcere Pharmaceutical Co., Ltd
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-10
- **Primary completion:** 2009-10
- **Final completion:** 2010-10
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2010-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00813332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00813332, "Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00813332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*